Emd Serono patents expiration
1. Egrifta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5861379 | EMD SERONO | Chimeric fatty body-pro-GRF analogs with increased biological potency |
May, 2015
(8 years ago) | |
| US6020311 | EMD SERONO | GRF analogs with increased biological potency |
May, 2015
(8 years ago) | |
| US7144577 | EMD SERONO | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
Jul, 2020
(3 years ago) | |
| US7316997 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(8 months ago) | |
| US8435945 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(8 months ago) | |
| US8314066 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2015 |
Drugs and Companies using TESAMORELIN ACETATE ingredient
NCE-1 date: 10 November, 2014
Market Authorisation Date: 10 November, 2010
Treatment: Reduction of excess abdominal fat in hiv-infected patients with lipodystrophy
Dosage: POWDER;SUBCUTANEOUS
EGRIFTA family patents
2. Gonal-f patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767251 | EMD SERONO | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| US5767067 | EMD SERONO | Follicle stimulating hormone and pharmaceutical compositions containing same |
Jun, 2015
(8 years ago) | |
| US7563763 | EMD SERONO | FSH and FSH variant formulations, products and methods |
Aug, 2019
(4 years ago) | |
Drugs and Companies using FOLLITROPIN ALFA/BETA ingredient
Market Authorisation Date: 25 March, 2004
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
GONAL-F family patents
3. Gonal-f Rff patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767067 | EMD SERONO | Follicle stimulating hormone and pharmaceutical compositions containing same |
Jun, 2015
(8 years ago) | |
| US5767251 | EMD SERONO | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
Drugs and Companies using FOLLITROPIN ALFA/BETA ingredient
Market Authorisation Date: 25 March, 2004
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
GONAL-F RFF family patents
4. Gonal-f Rff Pen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767067 | EMD SERONO | Follicle stimulating hormone and pharmaceutical compositions containing same |
Jun, 2015
(8 years ago) | |
| US5767251 | EMD SERONO | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| US7446090 | EMD SERONO | FSH formulation |
Aug, 2019
(4 years ago) | |
| US7741268 | EMD SERONO | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
Apr, 2024
(a month ago) | |
Drugs and Companies using FOLLITROPIN ALFA/BETA ingredient
Market Authorisation Date: 25 November, 2019
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
GONAL-F RFF PEN family patents
5. Luveris patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767251 | EMD SERONO | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 08, 2011 |
Drugs and Companies using LUTROPIN ALFA ingredient
Market Authorisation Date: 08 October, 2004
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
LUVERIS family patents
6. Ovidrel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767251 | EMD SERONO | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| US6706681 | EMD SERONO | HCG liquid formulations |
Mar, 2021
(3 years ago) | |
Drugs and Companies using CHORIOGONADOTROPIN ALFA ingredient
Market Authorisation Date: 20 September, 2000
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS; INJECTABLE;INJECTION
OVIDREL family patents
7. Saizen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5898030 | EMD SERONO | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 16 January, 2007
Treatment: NA
Dosage: INJECTABLE;INJECTION
SAIZEN family patents
8. Serostim patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5898030 | EMD SERONO | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 25 July, 1997
Treatment: NA
Dosage: INJECTABLE;INJECTION
SEROSTIM family patents
9. Zorbtive patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5898030 | EMD SERONO | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 01 December, 2003
Treatment: NA
Dosage: INJECTABLE;INJECTION
ZORBTIVE family patents